Last reviewed · How we verify
SD-809
SD-809 is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces the packaging and release of monoamines in presynaptic neurons.
SD-809 is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces the packaging and release of monoamines in presynaptic neurons. Used for Tardive dyskinesia, Chorea associated with Huntington's disease.
At a glance
| Generic name | SD-809 |
|---|---|
| Also known as | Deutetrabenazine; TEV-50717, deutetrabenzine, Austedo, deutetrabenazine, Deutetrabenazine |
| Sponsor | Auspex Pharmaceuticals, Inc. |
| Drug class | VMAT2 inhibitor |
| Target | VMAT2 (Vesicular Monoamine Transporter 2) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting VMAT2, SD-809 depletes intracellular stores of dopamine, serotonin, and norepinephrine, leading to reduced neurotransmitter availability in the synapse. This mechanism is thought to reduce involuntary movements and hyperkinetic symptoms. The drug crosses the blood-brain barrier to exert central nervous system effects.
Approved indications
- Tardive dyskinesia
- Chorea associated with Huntington's disease
Common side effects
- Parkinsonism
- Akathisia
- Sedation
- Depression
- Anxiety
Key clinical trials
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease (PHASE2, PHASE3)
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (PHASE4)
- Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD (PHASE1)
- An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia (PHASE1, PHASE2)
- A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy (PHASE3)
- A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (PHASE3)
- Reducing Involuntary Movements in Participants With Tardive Dyskinesia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |